Website Search
ID 15712

Bud and Yvonne

Description:
Diagnosed with chronic myeloid leukemia (CML), Bud noticed an article in the newspaper on Brian Druker's research. Bud and his wife Yvonne contacted Druker in 1996, and Bud was the first patient to receive the drug STI-571 (Gleevec) in clinical trials.
Keywords:
chronic myeloid leukemia,brian druker,drug sti,recovery thanks,gleevec,cml,yvonne,bud,leukemia,clinical trials
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15714. Brian Druker
Brian Druker is a professor at Oregon Health Sciences University.
15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
16105. The magic pills, Bud and Yvonne
Yvonne talks about the magic pills Bud took.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving